^
BIOMARKER:

RET fusion

i
Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
Entrez ID:
Phase 1/2
Hoffmann-La Roche
Recruiting
Last update posted :
07/30/2021
Initiation :
03/17/2017
Primary completion :
12/31/2021
Completion :
02/29/2024
RET • CEACAM5
|
RET fusion • RET mutation • RET rearrangement
|
Gavreto (pralsetinib)
Phase 1
Boston Pharmaceuticals
Recruiting
Last update posted :
07/23/2021
Initiation :
12/12/2018
Primary completion :
12/01/2021
Completion :
12/31/2021
RET
|
RET fusion • RET mutation
|
zeteletinib (BOS-172738)
Phase 2
Genentech, Inc.
Recruiting
Last update posted :
07/22/2021
Initiation :
11/06/2020
Primary completion :
08/15/2028
Completion :
08/15/2028
BRAF • ALK • RET • NTRK1 • NTRK3 • ROS1
|
BRAF mutation • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • RET fusion • ALK fusion • RET mutation • ROS1 fusion • ALK-ROS1 fusion
|
Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Cotellic (cobimetinib) • Alecensa (alectinib) • Gavreto (pralsetinib)
Phase 3
Loxo Oncology, Inc.
Recruiting
Last update posted :
07/19/2021
Initiation :
02/17/2020
Primary completion :
01/15/2023
Completion :
08/18/2025
RET
|
RET fusion • RET positive
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Retevmo (selpercatinib)
Phase 3
Loxo Oncology, Inc.
Not yet recruiting
Last update posted :
07/16/2021
Initiation :
10/31/2021
Primary completion :
08/31/2028
Completion :
11/30/2032
RET
|
RET fusion
|
Retevmo (selpercatinib)
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
07/16/2021
Initiation :
07/01/2012
Primary completion :
07/01/2022
Completion :
07/01/2022
RET • ROS1 • KIF5B • AXL • NTRK
|
RET fusion • MET overexpression • KIF5B-RET fusion • ROS1 fusion • AXL overexpression • NTRK fusion
|
Cabometyx (cabozantinib tablet)
Phase 1/2
Helsinn Healthcare SA
Recruiting
Last update posted :
06/18/2021
Initiation :
12/16/2020
Primary completion :
12/01/2023
Completion :
08/01/2024
RET
|
RET fusion
|
HM06
Phase 3
Hoffmann-La Roche
Recruiting
Last update posted :
05/27/2021
Initiation :
07/24/2020
Primary completion :
09/30/2023
Completion :
12/31/2024
RET
|
RET fusion
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Abraxane (albumin-bound paclitaxel) • pemetrexed • Gavreto (pralsetinib)
Phase 2
M.D. Anderson Cancer Center
Not yet recruiting
Last update posted :
05/19/2021
Initiation :
07/31/2021
Primary completion :
09/30/2022
Completion :
09/30/2022
EGFR • ALK • MET • RET • ROS1
|
RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • RET rearrangement • ROS1 fusion • ROS1 rearrangement
|
carboplatin • gemcitabine • Imfinzi (durvalumab) • Abraxane (albumin-bound paclitaxel) • pemetrexed
Phase 1/2
Turning Point Therapeutics, Inc.
Recruiting
Last update posted :
05/04/2021
Initiation :
12/16/2019
Primary completion :
05/01/2024
Completion :
03/01/2025
RET
|
RET fusion • RET mutation
|
TPX 0046
Phase 
Blueprint Medicines Corporation
Enrolling by invitation
Last update posted :
01/06/2021
Initiation :
12/01/2020
Primary completion :
05/31/2021
Completion :
10/31/2021
RET
|
RET fusion • RET positive
|
cisplatin • Gavreto (pralsetinib)
Phase 2
Samsung Medical Center
Completed
Last update posted :
12/07/2020
Initiation :
11/03/2014
Primary completion :
12/29/2014
Completion :
03/16/2018
RET
|
RET fusion
|
Caprelsa (vandetanib)
Phase 
University Hospital, Toulouse
Not yet recruiting
Last update posted :
11/10/2020
Initiation :
12/31/2022
Primary completion :
12/31/2022
Completion :
12/31/2022
EGFR • HER-2 • BRAF • ALK • TMB • MET • RET • ROS1 • NTRK
|
KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • HER-2 mutation • RET fusion • ALK rearrangement • RET mutation • ROS1 fusion • MET mutation • ROS1 rearrangement
Phase 2
Southwest Oncology Group
Recruiting
Last update posted :
11/09/2020
Initiation :
02/10/2020
Primary completion :
02/28/2023
Completion :
02/28/2023
EGFR • BRAF • KRAS • ALK • MET • RET • ROS1
|
BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive
|
Retevmo (selpercatinib)
Phase N/A
Blueprint Medicines Corporation
Available
Last update posted :
06/29/2020
EGFR • BRAF • ALK • RET • ROS1 • NTRK
|
EGFR mutation • BRAF mutation • RET fusion • RET mutation
|
Gavreto (pralsetinib)
Phase 2
University College, London
Recruiting
Last update posted :
06/12/2020
Initiation :
05/12/2017
Primary completion :
11/01/2024
Completion :
11/01/2025
EGFR • HER-2 • BRAF • ALK • RET
|
HER-2 amplification • BRAF V600 • RET fusion • ALK fusion
|
Zelboraf (vemurafenib) • Tecentriq (atezolizumab) • Kadcyla (ado-trastuzumab emtansine) • Alecensa (alectinib)
Phase 
Hunan Province Tumor Hospital
Recruiting
Last update posted :
03/26/2020
Initiation :
03/24/2020
Primary completion :
03/24/2021
Completion :
03/24/2022
RET
|
RET fusion • RET positive
Phase N/A
Samsung Medical Center
Recruiting
Last update posted :
01/22/2020
Initiation :
03/23/2016
Primary completion :
08/01/2020
Completion :
12/01/2020
RET • FGFR
|
RET fusion • RET positive
|
Sutent (sunitinib)
Phase 4
Samsung Medical Center
Recruiting
Last update posted :
12/30/2019
Initiation :
11/20/2017
Primary completion :
12/01/2020
Completion :
12/01/2020
RET
|
RET fusion • FGFR2 mutation • FGFR2 fusion • FGFR mutation • RET positive
|
Sutent (sunitinib)
Phase 2
National Taiwan University Hospital
Completed
Last update posted :
07/18/2018
Initiation :
01/01/2014
Primary completion :
02/01/2017
Completion :
02/01/2017
EGFR • HER-2 • BRAF • ALK • RET • ROS1 • EML4 • KIF5B • SLC34A2
|
BRAF V600E • EGFR mutation • BRAF mutation • BRAF V600 • EGFR T790M • HER-2 mutation • RET fusion • ALK positive • ALK rearrangement • EGFR exon 20 insertion • KIF5B-RET fusion • ALK fusion • RET mutation • HER-2 exon 20 insertion • ALK translocation • EGFR exon 20 mutation • BRAF G469A • BRAF D594G • TFG-ALK fusion • BRAF exon 15 mutation
|
luminespib (AUY922)
Phase 2
Tongji University
Recruiting
Last update posted :
09/04/2015
Initiation :
01/01/2015
Primary completion :
12/01/2016
Completion :
12/01/2017
RET
|
RET fusion • RET positive
|
AiTan (rivoceranib)